Company: MGLD
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001493152-25-009595
Chunk: 20

Company: Marygold Companies, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 20
---
 2025, we closed on the sale of an aggregate of 2,050,000 shares of our common stock at a price to the public of $1.10 per share (before deduction of underwriting discounts payable to Maxim equal to 8% of the price to the public per share, or an aggregate of $180,400) in a firm commitment underwritten public offering for which Maxim acted as sole underwriter and book-running manager. In addition, we reimbursed Maxim’s counsel fees in the aggregate amount of $50,000. Further, in connection with the offering, pursuant to the underwriting agreement we entered into with Maxim, dated January 26, 2025 (“Underwriting Agreement”), we granted Maxim a 45-day option to purchase up to an additional 307,500 shares of common stock at the public offering price before deduction of underwriting discounts and commissions (“overallotment option”). As of the date of this prospectus supplement, Maxim has not exercised its overallotment option and there can be no assurance that it will do so. See “The Offering – Certain Recent Developments – Recent Equity Financing.”

Right of First Refusal

Pursuant to the terms of the Underwriting Agreement we entered into with Maxim in connection with our recent underwritten public offering, we agreed that, until and including January 25, 2026, Maxim will have a right of first refusal to act as sole managing underwriter and sole book runner, sole placement agent, or sole sales agent, for any and all future registered offerings or private placements of our equity, equity-linked or debt securities for which we retain the service of an underwriter, agent, advisor, finder or other person or entity in connection with such offering during such period. Also, we have agreed not to offer to retain any entity or person in connection with such an offering on terms more favorable that the terms on which we offer to retain Maxim.

Lock-Up Agreements

Subject to certain limited exceptions, upon closing of our recent underwritten public offering, we agreed until May 28, 2025, not to (i) offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities without Maxim’s prior written consent; and (ii) each of our directors, officers, and affiliates who were holders of our shares as of January 26, 2025, (and all holders of securities exercisable for or convertible into shares of our common stock) has agreed,